Join the Adzenys XR-ODT group to help and get support from people like you.
Adzenys XR-ODT News
Many ADHD Medications Lead to Increases in Blood Pressure and Heart Rate
MONDAY, April 21, 2025 – Many pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD) lead to increases in hemodynamic signs, including blood pressure and pulse, according to...
ADHD Drugs Generally Safe For Heart Health, Review Says
MONDAY, April 14, 2025 – Worried about taking the ADHD meds you’ve been prescribed because they might harm your heart health? There’s no need to fret, according to a new evidence review. ADHD med...
Rx Amphetamine Use Linked to Increased Odds of Psychosis, Mania
TUESDAY, Sept. 17, 2024 – Past-month prescription amphetamine use is associated with increased odds of psychosis and mania, with increased odds for high doses (>30 mg dextroamphetamine equivalents),...
Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER (amphetamine) Extended-Release Oral Suspension for ADHD
DALLAS and FORT WORTH, Texas, Sept. 15, 2017 (GLOBE NEWSWIRE) – Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT (Amphetamine Extended-Release Orally Disintegrating Tablet) for ADHD
DALLAS and FORT WORTH, Texas, Jan. 27, 2016 (GLOBE NEWSWIRE) – Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product c...
Further information
Related condition support groups
Attention-Deficit Hyperactivity Disorder (ADHD)